Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
Source: SeekingAlpha
2025-03-31 18:34:45 ET
More on AcelRx Pharmaceuticals
- Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
- AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09
- Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals
- Historical earnings data for AcelRx Pharmaceuticals
- Financial information for AcelRx Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
Talphera Inc.
NASDAQ: TLPH
TLPH Trading
-7.66% G/L:
$0.7955 Last:
47,338 Volume:
$0.80 Open:
TLPH Latest News
March 02, 2026 08:30:00 am
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
November 12, 2025 04:05:00 pm
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025 09:28:49 am
Spider Silk, Strong Earnings, and Biotech Resilience Define the Midweek Momentum
November 05, 2025 04:05:00 pm
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
TLPH Stock Data
$39,152,079
25,309,023
0.41%
12
N/A
Pharmaceuticals
Healthcare
US
San Mateo
